Long-term echographic monitoring of children with schistosomiasis haematobia after praziquantel
Long-term echographic monitoring of children with schistosomiasis haematobia after praziquantel
复制标题
DOI：
10.1046/j.1365-3156.2001.00660.x
复制
发表时间：
2001-01-01
影响因子：
3.3
通讯作者：
Chippaux, JP
中科院分区：
文献类型：
--
作者：
Campagne, G;Garba, A;Chippaux, JP
在尼日尔的一项埃及血吸虫病控制计划中，我们进行了一项调查，以描述吡喹酮治疗后病变的消退情况，确定再感染率并确定再治疗时间表。在初步评估和服用40 mg/kg吡喹酮后，居住在高流行村的114名学童（7-15岁）在34个月内连续接受了10次检查。所有儿童，无论是否明显感染了S。无论是否感染了埃及血吸虫，均进行了治疗。评估卵子排出量、显微血尿、尿液外观和超声检查尿路异常。初始感染率为74.5%。治疗后5个月开始再感染，最终感染率为47.1%。膀胱异常下降迅速，但不完全，可能是由于再感染（初始患病率：89.5%）。他们的患病率在治疗后8个月增加到第34个月的72.4%。上尿路扩张消退较慢，但持续至研究结束（初始患病率：43%;第34个月时为4.6%）。治疗后3年，尽管再次感染，但我们队列的总体发病率水平（患病率和病变严重程度）低于基线水平，这表明在我们调查的流行病学背景下，大规模治疗之间间隔较长的优势。
During a Schistosoma haematobium morbidity control program in Niger, we conducted a survey to describe the resolution of lesions after treatment with praziquantel, to determine reinfection rates and to define retreatment schedules. 114 schoolchildren (7-15 years old) living in an hyperendemic village underwent 10 successive examinations over 34 months following an initial evaluation and the administration of 40 mg/kg of praziquantel. All children, whether apparently infected with S. haematobium or not, were treated. Egg output, microhaematuria, visual aspect of urine and abnormalities of the urinary tract by ultrasound were assessed. The initial prevalence of infection was 74.5%. Reinfection began 5 months after treatment and the final prevalence was 47.1%. Bladder abnormalities decreased rapidly but incompletely, probably due to reinfestation (initial prevalence: 89.5%). Their prevalence increased 8 months after treatment to 72.4% at month 34. Dilatations of the upper urinary tract regressed more slowly but constantly until the end of the study (initial prevalence: 43%; 4.6% at month 34). Three years after treatment, despite reinfection, the general morbidity level (prevalence and severity of lesions) was lower than at baseline in our cohort, which would suggest the advantage of a long interval between mass treatments in the epidemiological context of our survey.